DocGo's Q4 2025: What's Priced In After a Year of Misses?

The market's recent experience with DocGo has been one of persistent disappointment. Over the past year, the company has delivered a series of significant earnings misses, setting a low bar for expectations. The pattern is stark: in Q3 2025, DocGo reported an EPS of -$0.28, missing forecasts by a staggering 133.33%. That miss followed an even larger shortfall in Q2, where EPS missed by 266.67%, and a 550% miss in Q1. This relentless series of negative surprises has created a clear expectation gap.

The stock's price action since that last earnings release reflects the market's jaded sentiment. Following the Q3 report on November 10, 2025, shares have drifted -14.9% lower over the subsequent 57 days. More telling is the trading range, which has compressed between $0.86 and $1.11. The stock's current price near $0.94 sits close to the lower end of that band, indicating a market that has largely written off recent performance and is pricing in continued headwinds.

The implication is that negative sentiment has been partially, if not fully, priced in. After a year of earnings misses and a stock that has lost nearly 15% of its value since the last print, the easy bear case has been exhausted. The setup now hinges on whether execution in the coming quarters can outperform the deeply pessimistic view that the market has already baked into the share price. For a "beat and raise" scenario to play out, DocGo will need to demonstrate that its operational challenges are less severe than feared, turning the current expectation gap into a positive surprise.

The Q4 2025 Forecast: A Whisper Number of -0.144 EPS

The market's consensus for DocGo's upcoming fourth-quarter report is a clear blueprint for more bad news. The analysts project an EPS of -$0.14 and revenue of $70.16 million. This forecast is not a surprise; it is the expectation. The key detail is that these estimates have been frozen over the past three months, with revenue estimates for FY2025 unchanged by 0% and EPS estimates similarly stagnant. This lack of revision signals that the analyst community has set its expectations in stone, offering no new optimism or fresh pessimism.

The expected "bad news" is already well-defined. The primary pressure point is the continued wind-down of the migrant-related programs that once fueled growth. In Q3 2025, these programs still contributed $8.4 million in revenue. With that base eroding further, the market is pricing in a sequential decline in the core Mobile Health Services segment, which is the direct beneficiary of that work. The consensus EPS of -$0.14 is a direct reflection of that anticipated revenue drag and the associated margin pressures.

This frozen consensus creates a specific setup for the earnings day. If DocGo reports exactly to these numbers, the stock is likely to see a muted reaction or even a "sell the news" move. The market has already priced in the expected decline. The real opportunity for a positive surprise would come from beating this whisper number of -$0.14 EPS, perhaps by showing that the non-migrant revenue streams are holding up better than feared. Conversely, any miss on this already-low bar would confirm the worst-case scenario and likely trigger another leg down. For now, the expectation gap is closed, leaving the stock vulnerable to any deviation from the frozen forecast.

The Core Business Reality: Sandbagging or Recovery?

The headline revenue number tells one story, but the underlying business shows a more complex picture. The market has correctly priced in the collapse of the migrant programs, which drove total revenue down from $138.7 million to $70.8 million year-over-year. Yet, that decline masks a core business that is still expanding. Excluding those programs, revenue actually grew 8% to $62.4 million. More specifically, the medical transportation segment, which is the larger and more stable part of the business, saw its revenue climb $50.1 million, up from $48 million last year. This is the operational reality: the engine is still running, just not as fast as before.

The critical expectation gap now lies in profitability. The market is pricing in a revenue decline, but the deterioration in the bottom line is even more severe. Adjusted EBITDA swung from a $17.9 million profit to a $7.1 million loss in just one quarter. This isn't just a story of lost top-line growth; it's a story of collapsing margins and profitability. The company is burning cash at a faster rate, which is a major red flag that the market must now reassess.

Yet, there is a signal of operational efficiency that suggests the company is not in freefall. Despite the net loss, DocGo generated $1.7 million in operating cash flow last quarter. This is a crucial distinction: the business is still producing cash from its core operations, even as it grapples with the legacy of the migrant program wind-down and the costs of its recent acquisition. It indicates that the core model, particularly in transportation, has some inherent cash-generating power.

The bottom line is that the "bad news" is indeed in the price, but it's a partial picture. The market has priced in the revenue drop from migrant programs, but the deeper issue is the sharp contraction in profitability. For the stock to move higher, DocGo will need to show that the core business's expansion can eventually offset these margin pressures, turning the current cash burn into a path toward the guided EBITDA losses for 2026. The cash flow generation is a positive sign, but it doesn't change the fact that the company is losing money at a much faster rate than a year ago.

Catalysts and Risks: The 2026 Guidance Reset

The real test for DocGo's stock isn't just the Q4 print against the whisper number; it's the forward guidance that will reset expectations. Management has laid out a clear, if cautious, path for 2026, and the market will scrutinize every detail for signs of recovery or further deceleration.

The most significant forward-looking element is the 2026 revenue guidance of $280 million to $300 million. This implies 12% to 20% growth over the 2025 base. On the surface, that's positive growth. But viewed against the context of a business that has seen total revenue nearly halved year-over-year, this is a major deceleration from prior expansion rates. The market has priced in the collapse of the migrant programs, but it will now price in the new, slower growth trajectory. The guidance sets a new, lower bar for top-line momentum.

Management is signaling a push to scale the core business to hit these numbers. A key catalyst is the plan to hire 700 to 800 new staff to meet demand. This focus on hiring indicates a deliberate effort to ramp up capacity in the medical transportation segment, which is the larger and more stable part of the business. It's a bet that the underlying demand for transport services is strong enough to support this expansion, even as the mobile health segment continues to shrink.

Yet the primary risk is that the Q4 results and this 2026 guidance confirm a structural slowdown. The company's own numbers show the core business is still growing, but profitability is collapsing. If the guidance for 2026, which includes a projected adjusted EBITDA loss of $15 million to $25 million, is seen as too high or too slow to improve, it could trigger a "sell the news" reaction. The market has already priced in a year of misses and a depressed stock price. Any confirmation that the path to profitability is longer or more costly than hoped would likely lead to another leg down, even if the Q4 EPS print beats the whisper number of -$0.14. The expectation gap has been closed for the near term, but the forward view is the new battleground.